FluentPlay is a real-time voice-driven digital therapeutic platform for stuttering. Every disfluency event triggers cortisol. Repeated events condition the brain to release cortisol before the word is even attempted. FluentPlay breaks that loop — lowering cortisol during sessions, weakening the conditioned response over time, and preparing users for real-world speech with less fear. No one else is here. The circuit is unmapped. The market is unowned.
Stuttering affects approximately 3 million adults in the United States. There is currently zero pharma presence, zero FDA-cleared digital therapeutics, and no existing intervention that targets pre-articulatory planning — the stage where stuttering originates.
The basal ganglia-thalamocortical loop that controls motor gating for speech is the shared substrate. Both conditions involve involuntary disruption of speech output through circuit-level timing failure — but at different nodes.
Every stuttering event is a neurochemical event. Understanding that loop is what makes drug-free intervention possible.
Game-based therapy creates a low-stakes repetition environment where the motor sequence can fire repeatedly without triggering the full threat response. Each successful production reduces the conditioned cortisol spike. Over sessions, the anticipatory response attenuates — the amygdala stops flagging that sequence as dangerous. The wiring rewrites.
This is not relaxation therapy. It is structured neurochemical habituation through controlled motor repetition — measurable through PAD scoring, achievable without pharmacological intervention.
FluentPlay is conducting ongoing research into the relationship between PAD-scored acoustic features and cortisol-mediated motor disruption, with the goal of validating game-based intervention as a measurable, drug-free therapeutic pathway for speech-motor fluency.
PAD models disfluency as the product of Pressure and Anxiety — not the sum. This multiplicative relationship means a targeted intervention on one factor produces outsized reduction in the disfluency signal. It behaves like a dose-response curve.
Drag the sliders. Watch what happens to the disfluency signal when you cut just one input.
Clinical implication: FluentPlay's six game modes each target Pressure, Anxiety, or both. Summit (exposure therapy) reduces Pressure through repetition. Rainbow Syllables reduces Anxiety through real-time feedback. The multiplicative structure means partial reduction in either factor yields disproportionate clinical gain — without pharmacological intervention.
The PAD framework produces per-syllable, per-round analytics. Below is data from a session — four rounds of "The cat sat on the mat" — showing system stabilization in real time.
FluentPlay is developing a wearable fNIRS protocol in collaboration with NIRx to characterize pre-SMA hemodynamic activation during speech planning. This is the bridge from acoustic inference to direct neural measurement — transforming FluentPlay from a consumer tool into a biomarker-backed digital therapeutic.
Core hypothesis: Stuttering reflects predictable instability during pre-articulatory planning — measurable via hemodynamic response in the pre-SMA before articulation onset. If validated, PAD scores become a non-invasive proxy for a neural biomarker, enabling clinical trial endpoints without imaging.
FluentPlay is acquirable at pre-Phase I cost with a differentiated IP position, a working consumer product, and a biomarker development pathway.
Interested in exploring a strategic conversation?
willcarbone@fluentplaytech.com